We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The puzzle of antiplatelet therapy in ACS: ticagrelor monotherapy is another missing piece.
- Authors
Broek, Wout W A van den; Berg, Jurriën M ten
- Abstract
The article discusses the use of antiplatelet therapy in patients with acute coronary syndrome (ACS) and the balance between ischaemic and bleeding risks. The standard treatment for ACS involves dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor for 12 months. However, this increases the risk of bleeding. Recent studies have explored the use of ticagrelor monotherapy after a short period of DAPT, which has shown a reduction in bleeding rates without an increase in ischaemic events. However, the applicability of these findings to different patient populations and the role of genetic testing in selecting the appropriate antiplatelet therapy remain uncertain. Physicians should evaluate each patient individually to create a personalized antithrombotic strategy.
- Subjects
ACUTE coronary syndrome; DRUG accessibility; ST elevation myocardial infarction; PLATELET aggregation inhibitors; DRUG-eluting stents; MYOCARDIAL infarction
- Publication
European Heart Journal, 2024, Vol 45, Issue 33, p3057
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehae440